We are hereby submitting the monitoring agency report for the quarter ended 31st March, 2026
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kilitch Drugs submitted its Q4FY26 Monitoring Agency Report for a Rs. 49.92 crore Rights Issue completed in August 2025. Of the net proceeds of Rs. 49.45 crore, Rs. 48.33 crore has been utilized (97.7%), with Rs. 1.12 crore remaining idle in bank FDs earning 6.35% interest. The Greenfield project at Pen, Maharashtra is complete, but Rs. 1.12 crore designated for General Corporate Purposes remains unutilized due to pending final inspection of the project. The company reallocated Rs. 0.72 crore from GCP to capex during Q4FY26 as the original capex allocation was fully exhausted. No material deviation from the offer document objects was reported, with utilization verified by statutory auditors.
The report confirms proper utilization of rights issue proceeds with no deviations. The 3-month delay in GCP utilization due to pending project inspection is minor and expected to be resolved in Q1FY27. Shareholders can note that the greenfield expansion project is complete and capital deployment is substantially finished.